Thermo Fisher Scientific has announced a collaboration with Scinogy to develop and commercialize fit-for-purpose instrumentation and reagent systems aimed at improving productivity and scalability of cell and gene therapy manufacturing.
Thermo Fisher's collaboration with Scinogy will provide closed, modular, automated systems designed to enable scalable, cost-effective cell and gene therapy development and manufacturing.
"The cell therapy industry is expanding steadily, and Thermo Fisher Scientific is committed to empowering developers to accelerate the time between R&D to full-scale manufacturing and commercialization," said Amy Butler, vice president and general manager of cell biology at Thermo Fisher Scientific. "The team at Scinogy has an impressive track record of developing manufacturing systems that deliver high-quality, affordable cell and gene therapies, ultimately helping increase access to life-saving therapies around the world."
As an initial result of the collaboration, Thermo Fisher will unveil the new Gibco CTS Rotea Counterflow Centrifugation System at the International Society for Cellular Therapy meeting in Melbourne. The Rotea counterflow centrifuge is a highly reproducible, closed cell processing system designed for separation, washing and concentration of both autologous and small-scale allogeneic cell therapy samples.
"The Rotea counterflow centrifuge is the first in a family of manufacturing technologies being developed to suit the specific challenges and needs of the cell and gene therapy industry," said Bryan Poltilove, general manager of cell and gene therapy at Thermo Fisher Scientific. "The compact size, process flexibility and single-use kit allow the system to seamlessly scale from research through commercial manufacturing."